Andrea Cassingena
Andrea Cassingena
Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda
Verified email at ospedaleniguarda.it
TitleCited byYear
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
Nature Medicine, 2015
5392015
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ...
Cancer discovery 3 (6), 658-673, 2013
4532013
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of …
A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ...
The Lancet Oncology 17 (6), 738-746, 2016
3382016
The genomic landscape of response to EGFR blockade in colorectal cancer
A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou, B Lupo, M Sausen, ...
Nature 526 (7572), 263, 2015
2402015
Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer
A Amatu, A Sartore-Bianchi, C Moutinho, A Belotti, K Bencardino, ...
Clinical cancer research 19 (8), 2265-2272, 2013
872013
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer
L Barault, A Amatu, FE Bleeker, C Moutinho, C Falcomata, V Fiano, ...
Annals of oncology 26 (9), 1994-1999, 2015
712015
Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer
C Moutinho, A Martinez-Cardús, C Santos, V Navarro-Pérez, ...
JNCI: Journal of the National Cancer Institute 106 (1), 2014
672014
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer
L Barault, A Amatu, G Siravegna, A Ponzetti, S Moran, A Cassingena, ...
Gut 67 (11), 1995-2005, 2018
522018
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF-mutant colorectal cancer
D Oddo, EM Sennott, L Barault, E Valtorta, S Arena, A Cassingena, ...
Cancer research 76 (15), 4504-4515, 2016
502016
Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer
A Sartore-Bianchi, K Bencardino, A Cassingena, F Venturini, C Funaioli, ...
Cancer treatment reviews 36, S1-S5, 2010
422010
Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic …
A Sartore-Bianchi, K Bencardino, F Di Nicolantonio, F Pozzi, C Funaioli, ...
Targeted oncology 5 (1), 19-28, 2010
352010
Mutation-enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced cancers
T Fujii, A Barzi, A Sartore-Bianchi, A Cassingena, G Siravegna, DD Karp, ...
Clinical Cancer Research 23 (14), 3657-3666, 2017
292017
Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer
G Siravegna, L Lazzari, G Crisafulli, A Sartore-Bianchi, B Mussolin, ...
Cancer Cell 34 (1), 148-162. e7, 2018
212018
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013; 3: 658–673. doi: 10.1158/2159-8290
A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ...
CD-12-0558.[PMC free article][PubMed][Cross Ref], 0
20
Abstract CT005: final results of the HERACLES trial in HER2-amplified colorectal cancer
S Siena, A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, ...
Cancer Research 77 (13 Supplement), CT005-CT005, 2017
182017
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer
A Amatu, L Barault, C Moutinho, A Cassingena, K Bencardino, S Ghezzi, ...
Annals of Oncology 27 (6), 1062-1067, 2016
182016
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal …
A Sartore-Bianchi, F Pietrantonio, A Amatu, M Milione, A Cassingena, ...
European Journal of Cancer 71, 43-50, 2017
142017
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor
G Siravegna, A Sartore-Bianchi, B Mussolin, A Cassingena, A Amatu, ...
Annals of Oncology 28 (6), 1302-1308, 2017
122017
Pooled analysis of clinical outcome of patients with chemorefractory metastatic colorectal cancer treated within phase I/II clinical studies based on individual biomarkers of …
A Sartore-Bianchi, A Amatu, E Bonazzina, S Stabile, L Giannetta, G Cerea, ...
Targeted oncology 12 (4), 525-533, 2017
62017
Plasma HER2 (ERBB2) copy number to predict response to HER2-targeted therapy in metastatic colorectal cancer.
A Bardelli, G Siravegna, A Sartore-Bianchi, RJ Nagy, B Mussolin, ...
Journal of Clinical Oncology 36 (15_suppl), 3506-3506, 2018
52018
The system can't perform the operation now. Try again later.
Articles 1–20